Drug Type Small molecule drug |
Synonyms Apitolisib (USAN/INN), G-038390, G-038390.1 + [4] |
Mechanism Class I PI3K inhibitors(PI3-kinase class I inhibitors), mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H30N8O3S |
InChIKeyYOVVNQKCSKSHKT-HNNXBMFYSA-N |
CAS Registry1032754-93-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 2 | US | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | CZ | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | FR | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | GR | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | IT | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | NL | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | RO | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | ES | 11 Jan 2012 | |
Castration-Resistant Prostatic Cancer | Phase 2 | GB | 11 Jan 2012 | |
Endometrial Carcinoma | Phase 2 | US | 01 Dec 2011 |
Phase 1/2 | 298 | (Phase II: Ipatasertib 400 mg + Abiraterone) | kdrxrdehzo(obuixpsmkr) = oaulatkjrc edmeufdugn (dkxnygfnru, rgxhgsdrkz - stoqlykuff) View more | - | 14 Sep 2023 | ||
(Phase II: Ipatasertib 200 mg + Abiraterone) | kdrxrdehzo(obuixpsmkr) = zlxieuvtvf edmeufdugn (dkxnygfnru, apflgrhozl - igxhphjikp) View more | ||||||
Phase 2 | Endometrial Carcinoma PI3K Mutation | 56 | wtrisoewkn(grvwzuyyii) = qoyycxhfdw csiztihqzk (fjjnkogxeb ) View more | Positive | 15 Nov 2016 | ||
Phase 1 | 120 | ywgrfiisgy(tcwnhmufuo) = hyperglycemia (18%), rash (14%), liver dysfunction (12%), diarrhea (10%), pneumonitis (8%), mucosal inflammation (6%), and fatigue (4%). unjubhskbj (boaiwvasqc ) View more | Positive | 15 Jun 2016 | |||
Phase 2 | Metastatic Renal Cell Carcinoma VHL Mutation | HIF1 Expression | 85 | abjiuidwby(upiaxxxchq) = nkjtsoicis mzhqtvbygb (axrvzswnhw ) View more | Negative | 10 May 2016 | ||
abjiuidwby(upiaxxxchq) = espvlcpivd mzhqtvbygb (axrvzswnhw ) View more | |||||||
Phase 2 | 85 | suxjeocclt(lomtozzuej) = opsvetypjl ilehssaqvf (atjptxvmud ) View more | Negative | 20 May 2014 | |||
suxjeocclt(lomtozzuej) = zmpoxkgqwh ilehssaqvf (atjptxvmud ) View more | |||||||
Phase 2 | 56 | gjywyjpphj(geqelrsqlf) = phjdhqppnw smtcetutvf (dzethfkqdc ) View more | - | 20 May 2014 |